Advanced Enzyme Technologies Limited (AETL) (NSE: ADVENZYMES; BSE: 540025) today announced that its systemic enzyme and probiotic supplements-ImmunoSEB and ProbioSEB CSC3 have passed the promising stages of randomized controlled clinical trials in terms of efficacy to resolve post-COVID fatigue symptoms.
It's a fact that muscle fatigue and cognitive disturbances persist in patients after recovery from acute COVID-19 disease. However, there are no specific treatments available globally to treat post-COVID fatigue complications.
With an aim to evaluate the efficacy and safety of the health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex) in patients suffering from COVID-19 induced fatigue, a randomized, multi-centric, double blind and placebo-controlled trial was conducted in 200 patients suffering from post-COVID fatigue symptoms.
The test arm (100 patients) received the oral supplements for 14-days and the control arm (100 patients) received placebo, informed Dr. Abhijit K. Rathi, Principal Scientist, AETL.
The randomized clinical trial was conducted on 200 patients that did not have an active SARS-CoV-2 infection, as determined by a negative COVID-19 test, with a complaint of post-COVID fatigue. Patients were required to have a positive COVID-19 test at any time in the past. The trial was conducted across three centres in India-Swasthya Hospital, Bhopal; Samvedna Hospital, Varanasi; and Chirayu Medical College & Hospital, Bhopal by Investigators for 14-days, informed Dr Rathi.
According to the clinical research paper published by the Switzerland-based "Medicines" Journal on August 30, 2021, the treatment efficacy was compared using the Chalder Fatigue Scale (CFQ-11) for 14-days. Interestingly, the supplemental treatment resulted in resolution of fatigue in a greater percentage in patients during the test as against the control arm (91% vs. 15%) during the 14-day trial. Patients in the test arm category showed a significantly greater reduction the overall physical and mental fatigue scores as against patients in the control arm segment. The supplements were well tolerated with no adverse events reported. This clinical study demonstrated that the 14-day supplementation of ImmunoSEB and ProbioSEB CSC3 resolved post-COVID-19 fatigue symptoms and improved patients' functional status and quality of life, informed Dr. Rathi.
The Coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a worldwide pandemic afflicting a large population across the globe. Most infected people develop acute symptoms that last for 7-10 days. However, one or more symptoms (physical, cognitive and/or psychological) persist for weeks or even months in a substantial percentage of people. Fatigue is the most persistent and debilitating symptom of long COVID.
Studies revealed that about 52 percent of patients among the studied population showed fatigue/myalgia post-COVID-19.
A survey done by the Office for National Statistics (ONS), United Kingdom suggests that about one in five people have symptoms of long COVID five weeks after an initial infection and one in ten after twelve weeks. The chronic phase of COVID-19 is conjectured to be perpetual, with impaired functional status and quality of life. Though the data on COVID fatigue is still emerging, viral infections are known to trigger chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME) in patients. There are no specific biomarkers, and diagnosis is typically based on symptoms.
"Enzymes and probiotics are a robust mechanism to revitalize stamina and vitality, which is proved during the recently concluded randomized clinical trials," said Mr. Vasant Rathi, Chairman, AETL.
"Recent trials suggest that nutraceuticals product supplement succours in recovery of COVID patients. However, the patient-oriented outcome of the supplement may vary in individuals. For some, they may find a difference within couple of days, but for others, it may take a week or ten days. To avail long-term benefit and better results of the supplement, it's advisable to take the immunity bundle doses consistently every day for couple of months. However, in case you miss the dosage, don't' worry as it has no side effects," said Mr. Rathi.
"We have served the Americans since over last 30 years. But during the pandemic, our key focus was to enhance immunity amongst Indians. Hence, we went online with our research-backed immunity bundle. I feel, doctors need to address the issue of post-COVID immunity soon as its affecting quality of life," said Mr. Mukund Kabra, Director, Advanced Enzyme Technologies Limited (AET).
To benefit common people our researched-backed chemical-free post-COVID immune support bundle - ImmunoSEB and Biome Ultra (ProbioSEB CSC3), our company has beefed up our omnichannel presence across India and globally. We tasted our runaway success in the US markets amidst the pandemic, hence decided to list our flagship immune support brands across online marketplaces in India to target a larger swath of pill-fatigued, healthy agers, immunity conscious millennials, and Gen Z, said Mr Kabra.
Meanwhile, the products are currently available globally on the leading e-commerce marketplace - Amazon. In a move to further shore up its direct-to-customer (D2C) omnichannel retailing business, AETL has unveil its online store - 'Advanced Enzymes e-Direct Store' in September 2021 to help customers choose from a wide range of health support products.
Shares of Advanced Enzyme Technologies Limited was last trading in BSE at Rs. 372.8 as compared to the previous close of Rs. 366.2. The total number of shares traded during the day was 11499 in over 735 trades.
The stock hit an intraday high of Rs. 375.55 and intraday low of 360. The net turnover during the day was Rs. 4236469.